Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.

At this year’s Morningstar Investment Conference in Chicago, Morningstar equity researchers will share their insights on the ...

Lilly has not revealed any plans to develop a subcutaneous form of Kisunla, but is developing both IV and subcutaneous forms of its follow-up amyloid drug remternetug, which is in phase 3 testing.

At the moment, there are two FDA-approved, antibody-based amyloid therapies for Alzheimer's – Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – which are given as infusions.